Contemporary pharmacological obesity treatments

• Main Authors: Kaszubska Katarzyna, Budzynska Barbara, Biala Grazyna
• Format: Article
• Language: English
• Published: Sciendo 2016-06-01
• Series: Current Issues in Pharmacy and Medical Sciences
• Subjects: pharmacotherapy; obesity; body mass index; drug
• Online Access: https://doi.org/10.1515/cipms-2016-0012

In the last few years, obesity has become a global epidemic. Consequently, worldwide costs associated with managing obesity and obesity-related comorbidities are huge. Numerous studies have focused on discerning the appropriate proper treatment of weight related problems such as overweight and obesity. Moreover, many clinical trials have been conducted for many years in order to introduce effective anti-obesity drugs. The aim of the present review is to provide an overview of current and future pharmacotherapy for obesity, and to provide the reader with a determination of the concentration and composition of long and short term anti-obesity drugs, doing so by placing emphasis on pharmacotherapy and up-to-day solutions. It should be noted that, currently, the worldwide pharmacotherapy is represented by phendimetrazine, benzphetamine and diethylpropion, as well as by orlistat, lorcaserin, phentermine/topiramate, naltrexone/bupropion and liraglutide. In our paper, individual cases of patients’ needs are thoroughly illustrated by way of examples. Medical prescriptions and contraindications are also described.